Background: Nanoparticle albumin-bound paclitaxel is indicated for the treatment of patients with lung cancer. It can induce interstitial lung disease, but the incidence of nanoparticle albuminbound paclitaxel-associated interstitial lung disease in clinical practice has not been determined. We investigated the incidence of interstitial lung disease in patients with lung cancer who had received nanoparticle albumin-bound paclitaxel therapy at our institution. Methods: We reviewed clinical data for patients with advanced lung cancer who received nanoparticle albumin-bound paclitaxel with or without carboplatin or bevacizumab therapy at the Nippon
Introduction
Paclitaxel (PTX) is widely used to treat lung cancer patients. It has some dose-limiting toxicities such as peripheral neuropathy, and unique hypersensitivity reaction caused by its solvent-based formulation. Therefore, premedication with corticosteroids and antihistamines is essential when using this agent. Nanoparticle albumin-bound PTX (nab-PTX) is a new formulation of PTX which binds human serum albumin. Nab-PTX is readily soluble in saline without solvent, thereby allowing a shorter infusion time and administration without premedication.
In a phase III trial of advanced non-small-cell lung cancer (NSCLC), first-line nab-PTX plus carboplatin therapy produced a higher objective response rate than solvent-based PTX plus carboplatin therapy (1) . Recently, a few reports have suggested that single-agent nab-PTX shows favorable response and good tolerance in treatment of advanced NSCLC (2, 3) . Since nab-PTX provides higher local concentration of PTX in the tumor microenvironment, adverse events such as peripheral neuropathy, neutropenia, arthralgia and myalgia occur less frequently than with solvent-based PTX (1) . Therefore, nab-PTX has been widely used in the treatment of advanced lung cancer. In phase III trials of pancreatic and gastric cancer, 1.2-4% of patients who received nab-PTX developed pneumonitis as an adverse event (4, 5) . Though we are not aware of any previous reports on detailed investigation of nab-PTX-associated interstitial lung disease (ILD) in clinical practice of the lung cancer treatment, few reports on the risk of acute exacerbation (AE) in patients with preexisting interstitial pneumonia (IP) associated with nab-PTX have been published (6) (7) (8) .
Thus, we conducted a retrospective study on ILD that included all patients with lung cancer who were treated with nab-PTX at our institution over a period of 4 years and 6 months. Thus, we conducted a retrospective study on ILD that included all patients with lung cancer who were treated with nab-PTX at our institution over a period of 4 years and 6 months.
Patients and methods

Patients and data collection
We retrospectively collected data for consecutive patients with lung cancer who were treated with nab-PTX at the Nippon Medical School Main Hospital from April 2013 to September 2017. The data included age, sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS), smoking history (including packyears), respiratory function, preexisting IP (recognized before the start of nab-PTX treatment), histological type of lung cancer, epidermal growth factor receptor (EGFR) mutations, stage of lung cancer, prior chemotherapy, prior thoracic radiotherapy, dose of nab-PTX, combination therapy, time to onset of ILD from the first and last administration of nab-PTX, medical treatment for ILD and outcome of treatment. To evaluate the incidence of ILD associated with nab-PTX therapy, data for patients who developed ILD after nab-PTX treatment were compared with data for non-ILD patients. The study was approved by the hospital's institutional review board.
Diagnosis of nab-PTX-associated ILD
Nab-PTX-associated ILD was defined on the basis of the criteria suggested by Camus et al. (9) as follows: (i) clinical symptoms, including fever, cough and dyspnea, and increases in laboratory data, such as Krebs von den Lungen 6 (KL-6) or lactate dehydrogenase; (ii) newly developed shadows on chest X-ray and computed tomography (CT); (iii) exclusion of other diseases, such as pulmonary infection, cardiogenic pulmonary edema and lymphangitic carcinomatosis and (iv) development within 3 months after the last cancer treatment to avoid underestimating the incidence of cancer treatment-related ILD.
Evaluation of chest CT findings relating to pneumonitis
Chest CT images taken before nab-PTX therapy and at the time of diagnosis of pneumonitis were reviewed by two independent pulmonologists with expertise in IP. For patients who did not undergo high-resolution CT (HRCT), conventional CT images were carefully assessed.
In each case, radiographic patterns of nab-PTX-associated ILD were classified, by using criteria for ILD, as (i) diffuse alveolar damage (DAD) pattern, (ii) non-specific interstitial pneumonia (NSIP) pattern, (iii) organizing pneumonia (OP) pattern, (iv) acute eosinophilic pneumonia pattern and (v) hypersensitivity pneumonia pattern (10) (11) (12) .
Cases of background IP (before nab-PTX therapy) were classified according to levels of certainty described in a statement from the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society and the Latin American Thoracic Association (13) . Cases that were 'inconsistent with usual interstitial pneumonia (UIP) pattern' were classified as non-UIP pattern, and cases that showed 'UIP pattern' or 'possible UIP pattern' were classified as UIP pattern.
Statistical analysis
To determine which patient characteristics were associated with ILD, Fisher's exact test and Student's t test were performed. We also calculated the odds ratios (ORs) and their corresponding 95% confidence intervals to compare the risk of ILD.
Results
Patient characteristics
A total of 110 lung cancer patients received nab-PTX between April 2013 and September 2017. The clinical characteristics of the lung cancer patients are shown in Table 1 . Their median age was 68 years, and the majority were male. The ECOG PS was 0 or 1 in 87.3% of patients, the predominant histological type was NSCLC (97.3%), and more than half of the patients had a stage IV cancer (50.9%). Prior chemotherapy had been administered to 61.8% of patients and prior thoracic radiotherapy had been used in 27 . Bevacizumab therapy was mainly given with the aim of reducing pleural effusion or ascites, based on a phase 2 study by Kitamura et al. (14) . .
Clinical features of patients who developed nab-PTXassociated ILD
Nine of the 110 lung cancer patients who had received nab-PTX (8.2%) developed ILD. The clinical characteristics and clinical course for each of these patients are summarized in Table 2 . All of them had a history of smoking. Six had an ECOG PS of 1 and three had an ECOG PS of 2. Five had recurrence of lung cancer after thoracic surgery or radiotherapy. The time from initiation of nab-PTX therapy to onset of ILD ranged from 14 to 211 days. The median blood level of KL-6 at baseline was 968.8 U/ml (range, 306.3-2301 U/ml).
Of the nine patients who developed ILD, eight were treated with corticosteroids and three received cyclophosphamide pulse therapy in addition to corticosteroid therapy. One patient had just stopped receiving nab-PTX therapy. An improvement in condition was seen for three of the nine patients with ILD, but the other six died from respiratory failure.
Two of the nine patients with ILD were treated with a second course of nab-PTX therapy because they experienced remarkable tumor regression during their first course of nab-PTX. ILD recurred in both of these patients and one of them died.
Radiographic and pathological evaluation of nab-PTXassociated ILD
When chest CT images were evaluated for the nine patients with nab-PTX-associated ILD, seven patients were found to have widespread ground-glass opacities and consolidation with traction bronchiectasis, suggesting DAD pattern pneumonitis. The other two patients had patchy air-space consolidations with predominantly subpleural and peribronchial distribution, consistent with OP pattern pneumonitis. Of the seven with DAD pattern pneumonitis, six had IP before nab-PTX treatment and met the criteria for AE of IP (15) . IP in background lung was categorized as UIP pattern for four patients, categorized as non-UIP pattern for two patients. Therefore, six of 42 patients with background IP developed AE, so the incidence of AE of preexisting IP was 14.3%.
An autopsy was carried out for one patient (case 5, Table 2 ). She had initially been diagnosed no concomitance of preexisting IP by a physician because reticular shadows were slight in her pretreatment chest CT image (Fig. 1A) . She developed acute respiratory failure with diffuse reticular shadows and ground-glass opacities on CT after treatment with nab-PTX (Fig. 1B) and died despite methylprednisolone pulse therapy. DAD accompanied by extensive hyaline membranes along alveolar septa and epithelial desquamation were observed in a lung specimen obtained at autopsy ( Fig. 1C and D) . In addition, focal chronic fibrotic lesions in the bottom region of the lung were found and were consistent with chronic IP finding as basic lesions in the background ( Fig. 1E and F ).
Incidence of ILD by baseline characteristics
The results of the univariate analyses of baseline characteristics for nab-PTX-associated ILD are shown in Table 3 . Univariate analyses revealed three factors that were significantly associated with nab-PTX-associated ILD. First, there was a large difference in the percentage of patients who had preexisting IP when the ILD and non-ILD groups were compared (88.9% vs 33.7%, respectively). ILD developed in 8 of 42 patients with preexisting IP (19.0%) and in 1 of 68 patients without preexisting IP (1.5%), and this was a statistically significant difference (P = 0.002 ORs = 15.8 (1.89-131.3)). Second, the incidence of nab-PTX-associated ILD was higher in patients receiving bevacizumab combination therapy than in those not receiving bevacizumab. Specifically, three of the five patients who received bevacizumab combination therapy in the present study developed ILD. Third, patients who received a lower dose of nab-PTX were more likely to develop ILD: ILD developed in 4 of 84 patients (4.8%) who received a full dose of nab-PTX, compared with 5 of 26 patients (19.2%) who received a lower dose of nab-PTX (ORs = 4.76 (1.17-19.3 
)).
A multivariate analysis was not performed in the present study because the sample size was too small to determine independent predictive factors of nab-PTX-associated ILD. IP, interstitial pneumonia; AE, acute exacerbation; KL-6, Krebs von den Lungen 6; FVC, forced vital capacity; EGFR, epidermal grown factor receptor; Nab-PTX, nanoparticle albumin-bound paclitaxel; UIP, usual interstitial pneumonia; PS, performance status. 
Discussion
Chemotherapy using nab-PTX has been trialed in patients with tumors of various organs, including lung, breast, pancreas and stomach. In a phase III trial of pancreatic cancer, 4% of patients who received carboplatin with nab-PTX treatment developed pneumonitis as an adverse event (4). In gastric cancer treatment, 1.2% of patients who received weekly nab-PTX monotherapy developed ILD (5) . Previous studies on nab-PTX-associated ILD in NSCLC suggested that the incidence was 0-8.3% even if patients had IP in their background lung (6-8). These incidence was not high in comparison to a recent retrospective study focusing on the risk of AE of IP in patients treated with platinumbased chemotherapy as the first-line treatment, 9 of 104 patients (9%) developed chemotherapy-related AE (16). However, the exact incidence of nab-PTX-associated ILD was unclear because these previous studies were small. Furthermore, no previous studies have focused on radiographic images and pathological findings in nab-PTXassociated ILD. In our study, we focused on ILD associated with nab-PTX treatment as an adverse event. We considered the radiographic features, treatment and prognosis of nine pneumonitis cases that we identified. This retrospective investigation is important for gaining a better understanding of nab-PTX-associated ILD. From a total of 110 lung cancer patients who received nab-PTX, we identified 9 patients who developed ILD (8.2%). Many of the cases of ILD were severe and progressed rapidly, and chemotherapy was discontinued in all cases. Six of the nine patients died, two improved after corticosteroid treatment and one improved only by drug holding. In a previous report, single-agent nab-PTX in second-line or post-second-line treatment for NSCLC induced ILD in 4 out of 67 patients (6.0%) (3). This is similar to the ILD incidence in our study.
Although no fatal cases of nab-PTX-associated ILD have been reported, the poor prognosis of ILD patients is partly explained by the HRCT pattern of ILD. Seven patients out of nine in our study had DAD pattern pneumonitis, and six of them died. DAD pattern is the most severe form of drug-induced lung injury and is associated with an unfavorable prognosis (11) . Two patients had OP pattern pneumonitis, which was successfully treated by corticosteroid therapy. OP pattern pneumonitis has a much better prognosis in patients with druginduced ILD than DAD pattern pneumonitis (17) . Autopsy specimens were obtained from one patient. They showed extensive hyaline membranes and epithelial desquamation with cytological atypia, suggesting exudative phase of DAD. Surgery or bronchoscopy could not be used in any of the patients to diagnose nab-PTX-associated ILD because of the patients' conditions. This is the first report of several cases of nab-PTX-associated ILD focusing on the pattern of ILD and prognosis. To date, no detailed reports on the pathology of nab-PTX-associated ILD have been published, and more information regarding lung pathology is needed.
In the present study, patients in the ILD group were more likely to have had a low dose of nab-PTX, bevacizumab combination therapy, and concomitant preexisting IP compared with patients in the non-ILD group. Preexisting pulmonary fibrosis is thought to be an important risk factor for ILD in patients receiving various types of chemotherapy for lung cancer (18, 19) . In our study, 8 patients out of 42 (7). The higher incidence of ILD in the present study is due, in part, to our definition of nab-PTX-associated ILD. In the present study, patients who developed ILD within 3 months after the last treatment were considered to have drug-induced ILD, and all patients were included in the nab-PTX-associated ILD group. Previous studies used 28 days as the cut-off point for the development of ILD and only included patients with DAD pattern pneumonitis (6) (7) (8) . If we use 28 days as the cut-off period for the diagnosis of ILD, the incidence of AE of preexisting IP decreases to 9.5% (4/42 patients). This incidence remains higher than in previous reports. Another possible explanation for the high incidence of AE of IP in the present study is the difference in patient characteristics between the present and previous studies (6) (7) (8) . Unlike previous studies, we included many patients who received nab-PTX as post-second-line chemotherapy. The 42 patients with IP in background lung received nab-PTX as follows: 27 received it as first-line chemotherapy, of whom 4 developed ILD (14.8%); 13 received it as second-line, of whom 2 developed ILD (15.4%); 1 received it as third-line and developed ILD (100.0%); 1 received it as fourth-line and developed ILD (100.0%). Although these data imply there is no statistical relationship between treatment line and ILD, there is a trend for ILD to develop in proportion with the number of prior chemotherapy attempts. Another possibility is differences in the pattern of IP in background lung. The incidence of ILD during chemotherapy for lung cancer differs according to the CT pattern (20) . A UIP pattern on CT significantly increases incidence of chemotherapy-induced AE of IP, compared with a non-UIP pattern (20, 21) . In the present study, the incidence of AE for patients with the UIP pattern was 20.0% (4/20 patients), compared with 9.1% (2/22 patients) for those with a non-UIP pattern. The incidence of nab-PTX-associated ILD did not differ significantly with different IP patterns (P = 0.193). It is difficult to explain why ILD occurred more frequently in our patients with IP.
We previously reported that the incidence of AE related to solvent-based PTX with carboplatin therapy was 5.6% at our institution (22) . But in our present study, incidence of AE associated with nab-PTX was higher. Since allergic reaction to nab-PTX is less common than allergic reaction to solvent-based PTX, Yasuda et al. suggested that the incidence of ILD during nab-PTX treatment would be lower than that during solvent-based PTX treatment (7) . A hypothesis is that differences in corticosteroid pretreatment affect the incidence of ILD. Concomitant use of corticosteroids in solventbased PTX might reduce the risk of drug-induced lung disease, which might explain why the incidence of AE associated with nab-PTX is higher than the incidence of AE associated with solventbased PTX. A prospective clinical trial that assesses the risks and benefits of nab-PTX, compared with solvent-based-PTX, in patients who have lung cancer with IP is needed.
In the present study, univariate analysis indicated that there was a significant correlation between bevacizumab combination therapy and a high incidence of ILD (ORs = 24.75 (3.45-177.4)). However, since only 5 of the 110 consecutive patients received bevacizumab in our study, our data cannot be used to conclude that bevacizumab is a true risk factor. Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) receptor. Whether or not anti-VEGF therapy increases the incidence of druginduced ILD is a topic of controversy. Enomoto et al. reported that the addition of bevacizumab to carboplatin and PTX therapy did not raise the AE of IP risk (23) . Nintedanib, a tyrosine kinase inhibitor (TKI) that targets VEGF receptor, platelet-derived growth factor receptor and fibroblast growth factor receptor is used to treat idiopathic pulmonary fibrosis, and it has been suggested that nintedanib reduces the risk of AE (24) . Conversely, cases of ILD during chemotherapy with bevacizumab have been reported in colorectal cancer patients (25) . Decrease in VEGF expression is associated with the initial phase of acute lung injury (26) . We reviewed the group of five patients who received bevacizumab. They had characteristics as follows: (i) all patients were men and have smoking history; (ii) the patients were younger than the patients who did not receive bevacizumab (the median age was 58, range, 42-60 years); (iii) three of the five patients had IP in their background lung; (iv) three of the five patients had pleural effusion or ascites; (v) treatment chemotherapy lines were relatively high (five patients received bevacizumab as second, second, second, third and fourth line, respectively). In these factors, IP and effusions were characteristic. Though preexisting IP was known risk factor of drug-induced ILD, pleural effusion and ascites were not previously reported. Kudoh et al. suggested that decrease in extension of normal lung was associated with the incidence of drug-induced ILD (18) . We checked all five patients who received bevacizumab, however, the extension of normal lung was not severely avoided by effusions in all cases. Taken together, although it might be just an overestimation, high tendency of nab-PTX associated ILD in bevacizumab combination therapy was partially depend on the high frequency of the background IP or pleural effusion or ascites. Recently, anti-angiogenic agents like bevacizumab were reported to stimulate the immune system via induction of a lymphocyte infiltration into tumor microenvironment and increase antitumor immune reaction in combination therapy with immune checkpoint inhibitors (27) . It might suggest that lymphocyte inflammation by bevacizumab had a role in nab-PTX-associated ILD. Further investigation is necessary to determine whether the addition of VEGF receptor inhibitors increases the pulmonary complications of standard chemotherapy.
Some of the patients in our study received nab-PTX in a phase II clinical trial which aimed to evaluate the optimal dose of nab-PTX for patients with pretreated advanced NSCLC (UMIN 000016932). Patients were assigned to either the 70 mg/m 2 group or the 100 mg/ m 2 group and received single-agent nab-PTX therapy as postsecond-line treatment. In another phase II study, weekly nab-PTX (75 mg/m 2 ) in combination with carboplatin in elderly patients with lung cancer showed favorable efficacy and was well tolerated (28) . At our institution, the nab-PTX dose was decided by a physician, based on clinical presentation. For this reason, patients with poor PS, elderly patients and those with a history of severe adverse events in prior treatment tended to receive nab-PTX at a dose of 70 mg/m 2 . This could be one reason why the patients who received a lower dose of nab-PTX were more likely to develop ILD in our study. We also estimated whether the total dose of nab-PTX is associated with the occurrence of ILD and found no relationship between them (data not shown). Moreover, the dose intensity did not change throughout nab-PTX treatment of patients in the present study. Many of the lung toxicities of chemotherapeutic agents are considered to be neither cumulative nor dose dependent (29) . We concluded that there was a coincidence caused by the background of the patients who received a lower dose of nab-PTX.
We identified two cases of recurrence of nab-PTX-associated ILD. One patient (case 3, Table 2 ) initially had grade 3 DAD pattern pneumonitis and was successfully treated with drug holding and steroid pulse therapy. He developed recurrent DAD pattern pneumonitis 14 days after nab-PTX therapy was restarted and died from respiratory failure. The other patient (case 4, Table 2 ) initially had grade 1 ILD featuring OP pattern and recovered by treatment with drug holding and oral steroid therapy. After nab-PTX therapy was restarted, she developed recurrent OP and again recovered with oral steroid therapy and discontinuation of chemotherapy. Chemotherapy rechallenge is generally regarded as dangerous. These patients received no other conventional chemotherapy regimens and achieved good disease control when first treated with nab-PTX. Therefore, nab-PTX therapy was restarted after strict informed consent regarding recurrent ILD risk, in accordance with each patient's wishes. However, we suggest that nab-PTX should not be restarted in patients who develop nab-PTX-associated ILD, especially severe DAD pattern pneumonitis.
The present study has several limitations. First, the present study was a small, retrospective study that was performed at a single center. Therefore, there could be various biases and confounding factors. In particular, chemotherapy regimens and the doses of anticancer agents were selected by each treating physician individually, and this may have led to biases. Second, a major limitation of the present study is that we could not undertake surgery or bronchoscopy to diagnose nab-PTX-associated ILD in all cases. Therefore, we could not confirm pathological diagnoses of ILD and completely exclude other diseases, such as pulmonary infection and lymphangitic carcinomatosis. Third, our definition of nab-PTXassociated ILD does not exclude the possibility of natural progression or AE of IP independent of chemotherapy. Fourth, we did not perform the multivariate study like multivariate logistic analysis or Cochran-Mantel-Haenszel measurement for the purpose of adjustment of confounding factors because sample size was too small to determine independent predictive factors of nab-PTX-associated ILD, according to the clinical statisticians' advice. Therefore, we could not help employing the conservative conclusion about the risk factors of nab-PTX-associated ILD.
In conclusion, nab-PTX-associated ILD occurred in 8.2% of patients in our study. Our finding of a high incidence of ILD that was seemingly associated with preexisting IP supports the need for additional studies including prospective clinical trials to assess the risk of nab-PTX in lung cancer patients with IP. In particular, based on the high rate of nab-PTX-associated ILD in patients receiving bevacizumab across our small number of cases, larger clinical studies need to be conducted to determine whether the addition of VEGF receptor inhibitors increases the risk of ILD with standard chemotherapy.
